Try­ing to shake up the Parkin­son's par­a­digm, Ab­b­Vie sub­mits NDA for con­tin­u­ous, 24-hour in­fu­sion ther­a­py

Ab­b­Vie is ap­proach­ing the FDA with a new ther­a­py to po­ten­tial­ly treat Parkin­son’s dis­ease, us­ing pro­drugs of two med­ica­tions com­mon­ly used for the con­di­tion.

The Big Phar­ma sub­mit­ted its NDA for AB­BV-951, a so­lu­tion of lev­odopa and car­bidopa pro­drugs be­ing eval­u­at­ed in ad­vanced Parkin­son’s pa­tients who don’t re­spond well to oral ther­a­py, Ab­b­Vie an­nounced Fri­day morn­ing. Re­searchers are hop­ing a pos­i­tive Phase III study that reads out in late Oc­to­ber will help move things along quick­ly at the agency.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER